Developer of behavioural biometric technology designed to recognize a wide range of human and non-human cybersecurity th
Developer of behavioural biometric technology designed to recognize a wide range of human and non-human cybersecurity threats.
Financial Software📍 Tel Aviv, IsraelFounded 2011
Current Valuation
$1.3B
as of 2024-Q2
UNICORN
QL Price
$1.3B
0% vs last round
QuantLogix's current estimate for BioCatch, published 2026-09-15 — in line with the last disclosed round of $1.3B (2024-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.3B
2024-Q2
weight 0.22
Secondary market print
$1.3B
2026-06-27
weight 0.62
How this price has held up
No round has priced for BioCatch since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-15 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, BioCatch, 2026-09-15 (30b4745eb1abf1b4).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is BioCatch going public?
No. BioCatch is private and has not filed to go public. There is no S-1 on file.
What is BioCatch's valuation in 2026?
BioCatch is valued at $1.3B as of 2024-Q2, set by its Majority Interest Acquisition (May 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has BioCatch filed an S-1?
No public S-1 is on file for BioCatch.
Can you buy BioCatch stock?
No. BioCatch is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for BioCatch on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2011
HQ
Tel Aviv, Israel
Employees
400
Total Raised
$302.09M
IPO Status
private
Fundraising Status
Majority Interest Acquisition · 2y 4mo ago
privateTotal raised $302.09M
Secondary Market
Implied price / share
$3.51
Open interest
2
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Majority Interest Acquisition
—
May 2024
—
$1.3B
Talent Signal
Hiring trend
▼ Hiring downtrend
0% of roles posted in last 30d
Open roles
13
via lever
Product-build share
46%
engineering, research, product, design
Trajectory
tightening
product-led hiring — 46% of open roles build product; the rest are go-to-market and G&A.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Data ScientistSenior Backend DeveloperSenior Backend Engineer (Data Platform Group)Senior Data EngineerSenior DevOps Infra EngineerThreat Analyst
Counted from BioCatch's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q2. Refreshed quarterly.